Everything below concerns DMSO stock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Mostly in the 1990s, several books were published that were critical of cold fusion research methods and the conduct of cold fusion researchers. Over the years, several books have appeared that defended them. Around 1998, the University of Utah had already dropped its research after spending over $1 million, and in the summer of 1997, Japan cut off research and closed its own lab after spending $20 million.
The UK provides the Operational Ration Pack, General Purpose. Packed inside a small cardboard box, each ration has enough retort-pouched and canned foods to feed one soldier for 24 hours. Seven menus (plus vegetarian and religious variants) provide two precooked meals (Breakfast and Main Meal) plus a midday snack. Example (Menu A) Breakfast: Hamburger and beans, Instant Porridge. All ration packs also contain Oatmeal Block, Fruit Biscuits, Biscuits Brown (a more compact alternative to bread), a sachet of instant soup and jam or yeast extract (a Marmite like spread) for a lunchtime snack, and chocolate (in the form of a specially made Yorkie bar which is flatter than civilian bars, or, more recently, a simple unbranded bar of milk chocolate), though this has been phased out with the introduction of the more recent multi-climate ration packs, and boiled sweets (hard candy) for snacking whilst on patrol, or in free time. Main Meal: Instant soup, Chicken with Mushroom and Pasta, Treacle Pudding. Each pack also contains instant coffee, tea bags, creamer, sugar, hot cocoa mix, beef/vegetable stock powder, lemon/orange powder or Lucozade electrolyte powder, matches, packet of tissues, chewing-gum, a small bottle of Tabasco sauce, and water purifying tablets. They sometimes also contain chicken and herb pâté. Also available are Kosher/Halal, Vegetarian, and Hindu/Sikh specific menus. Regardless of their contents, these ration packs are referred to as Rat-Packs or Compo (short for Composite Rations) by the soldiers who eat them.
=== Pest control === Diatomite is of value as an insecticide because of its abrasive and physico-sorptive properties. The fine powder adsorbs lipids from the waxy outer layer of the exoskeletons of many species of insects. This layer acts as a barrier that resists the loss of water vapour from the insect's body. Damaging the layer increases the evaporation of water from their bodies, so that they dehydrate, often fatally. This also works against gastropods and is commonly employed in gardening to defeat slugs. However, since slugs inhabit humid environments, efficacy is low. Diatomaceous earth is sometimes mixed with an attractant or other additives to increase its effectiveness. The shape of diatoms has not been proven to affect their functionality as regarding adsorption of lipids. However, certain applications, such as that for slugs and snails, work best when a particularly shaped diatom is used, suggesting that lipid adsorption is not the only factor involved. For example, in the case of slugs and snails, large, spiny diatoms work best to lacerate the epithelium of the mollusk. Diatom shells will work to some degree on the vast majority of animals that undergo ecdysis in shedding cuticle, such as arthropods or nematodes. It also may have other effects on lophotrochozoans, such as mollusks or annelids. Medical-grade diatomite has been studied for its efficacy as a deworming agent in cattle; in both studies cited the groups being treated with diatomaceous earth did not fare any better than control groups.
Sources: en.wikipedia.org
== E == efficacy – empirical – encephalitis – end-stage disease – endemic – endogenous – endoscopy – endotoxin – endpoint – enteric – enteritis – entry inhibitors – Env – envelope – enzyme – enzyme-linked immunosorbent assay (ELISA) – eosinophil – eosinophilic folliculitis – epidemic – epidemiological surveillance – epidemiology – epithelium – epitope – Epstein-Barr virus (EBV) – erythema – erythema multiforme – erythrocytes – etiology – exogenous – exotoxin – expanded access – experimental drug – expression system
UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.
=== 1957 === January 5: The Eisenhower Doctrine commits the United States to defending Iran, Pakistan, and Afghanistan from Communist influence. January 22: Israeli forces withdraw from the Sinai, which they had occupied the previous year. February 15: Andrei Gromyko begins his long tenure as Foreign Minister of the Soviet Union. March 6: The Gold Coast becomes independent from the UK and renamed Ghana, which was under Commonwealth status. May 2: Senator Joseph McCarthy succumbs to illness exacerbated by alcoholism and dies. May 15: The United Kingdom detonates its first hydrogen bomb. August 31: Malaya gains independence from the United Kingdom. October 1: The Strategic Air Command initiates 24/7 nuclear alert (continuous until termination in 1991) in anticipation of a Soviet ICBM surprise attack capability. October 4: Sputnik 1 satellite launched. The same day the Avro Arrow is revealed. November 3: Sputnik 2 was launched, with the first living being on board, Laika. November 7: The final report from a special committee called by President Dwight D. Eisenhower to review the nation's defense readiness indicates that the United States is falling far behind the Soviets in missile capabilities, and urges a vigorous campaign to build fallout shelters to protect American citizens. November 15: Soviet leader Nikita Khrushchev claims that the Soviet Union has missile superiority over the United States and challenges America to a missile "shooting match" to prove his assertion. December 16–19: NATO holds its first summit in Paris, France.
== Epidemiology == The National Eye Institute reports keratoconus is the most common corneal dystrophy in the United States, affecting about one in 2,000 Americans, but some reports place the figure as high as one in 500. In the pediatric populations, ages three to 18, the prevalence of keratoconus was found to be as high as one in 334 children. The inconsistency may be due to variations in diagnostic criteria, with some cases of severe astigmatism interpreted as those of keratoconus, and vice versa. A long-term study found a mean incidence rate of 2.0 new cases per 100,000 population per year. Some studies have suggested a higher prevalence amongst females, or that people of South Asian ethnicity are 4.4 times as likely to develop keratoconus as Caucasians, and are also more likely to be affected with the condition earlier. Keratoconus is normally bilateral (affecting both eyes) although the distortion is usually asymmetric and is rarely completely identical in both corneas. Unilateral cases tend to be uncommon, and may in fact be very rare if a very mild condition in the better eye is simply below the limit of clinical detection. It is common for keratoconus to be diagnosed first in one eye and not until later in the other. As the condition then progresses in both eyes, the vision in the earlier-diagnosed eye will often remain poorer than that in its fellow.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.